Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GGB Awards Extend Entry Deadline To 26 August

Entry Period Extended By A Week Ahead Of 2 November Ceremony In Frankfurt

Executive Summary

Entrants now have an additional week to submit entries for the Global Generics & Biosimilars Awards 2022, which returns to Frankfurt this November.

You may also be interested in...



Tambe Moves Up To Lead Biocon Biologics

Shreehas Tambe has been named as CEO of Biocon Biologics, taking over from Arun Chandavarkar, in the wake of the company’s milestone $3bn transaction for Viatris’s biosimilars business.

Leonard Resignation Leaves AAM Looking For New Leadership

Dan Leonard has announced his resignation as president and CEO of the US Association for Accessible Medicines. He will be replaced on an interim basis by the group’s vice president for sciences and regulatory affairs, David Gaugh.

Humira Biosimilars Prepare For US Competition In 2023

The advent of biosimilar competition to Humira in the US in 2023 represents the largest loss-of-exclusivity opportunity ever for the off-patent industry. But with a host of biosimilar sponsors awaiting launches throughout the year, it remains to be seen how competition will play out.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB152099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel